Siglec and anti-Siglec therapies

Gavuthami Murugesan, Bernd Weigle, Paul R. Crocker (Lead / Corresponding author)

    Research output: Contribution to journalReview articlepeer-review

    51 Citations (Scopus)


    Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of receptors that bind sialic acids in specific linkages on glycoproteins and glycolipids. Siglecs play roles in immune signalling and exhibit cell-type specific expression and endocytic properties. Recent studies suggest that Siglecs are likely to function as immune checkpoints that regulate responses in cancers and inflammatory diseases. In this review, we discuss strategies to target the Siglec-sialic acid axis in human diseases, particularly cancer, and the possibility of exploiting them for therapeutic intervention.

    Original languageEnglish
    Pages (from-to)34-42
    Number of pages9
    JournalCurrent Opinion in Chemical Biology
    Early online date16 Feb 2021
    Publication statusPublished - Jun 2021


    • Siglec
    • Sialic acid
    • Cancer
    • Inflammation
    • Immune checkpoint

    ASJC Scopus subject areas

    • Analytical Chemistry
    • Biochemistry


    Dive into the research topics of 'Siglec and anti-Siglec therapies'. Together they form a unique fingerprint.

    Cite this